MD Anderson Study Status
EphA2-targeting DOPC-encapsulated siRNA
This phase I trial studies the side effects and best dose of EphA2 siRNA in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have come back after a period of improvement (recurrent). EphA2-targeting DOPC-encapsulated siRNA may slow the growth of tumor cells by shutting down the activity of a gene that causes tumor growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Advanced Malignant Solid Neoplasm
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.